Exelixis
EXEL
#1458
Rank
A$21.22 B
Marketcap
A$85.67
Share price
1.42%
Change (1 day)
45.38%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): A$4.86

According to Exelixis's latest financial reports the company's current EPS (TTM) is A$4.72. In 2025 the company made an earnings per share (EPS) of A$4.14.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$4.8617.57%
2025A$4.14
2023A$0.9314.61%
2022A$0.82-22.97%
2021A$1.06100%
2020A$0.53-65.09%
2019A$1.52-53.91%
2018A$3.29333.96%
2017A$0.76-260.61%
2016A-$0.47-58.75%
2015A-$1.14-42.45%
2014A-$1.995.3%
2013A-$1.89

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
A$12.50 164.66%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
A$1.09-76.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
A$23.21 391.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
A$2.72-42.34%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
A$1.81-61.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
A$6.50 37.58%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
A$4.58-3.10%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
A-$20.35-530.91%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
A-$1.20-125.45%๐Ÿ‡บ๐Ÿ‡ธ USA